Imagine Pharma, a biotech company focused on furthering the commercialization opportunities related to its novel IMG-1 polypeptide, today announced that it has raised a $32.5 million Series A round, with an initial traunch of $10 million, bringing its total funding to date to $40 million. The round was led by IP Investors LLC, a group of seasoned investors that focuses on biotech companies that have attainable solutions for unmet medical needs. John T. Callaghan, CPA CFE, representing the investor group, will join the board. The funding will be used to advance the company's priority programs in regenerative medicine, oral delivery, and therapeutics.

Imagine Pharma is a biotechnology company focused on the development of its IMG-1 polypeptide. Research and development efforts have led to the development of three distinctive platforms for Oral Delivery, Therapeutics, and Regenerative Medicine, each with first-in-class programs that address multiple disease states in large, underserved markets. Imagine Pharma is an approved Islet Isolation Center for the National Institute of Diabetes and Digestive and Kidney Diseases Integrated Islet Distribution Program. Imagine Pharma was founded in 2016.